![Jeffrey Feike](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Jeffrey Feike
No más puestos en curso
Fortuna: 470 071 $ al 31/05/2024
Cargos activos de Jeffrey Feike
Empresas | Cargo | Inicio | Fin |
---|
Historial de carrera de Jeffrey Feike
Antiguos cargos conocidos de Jeffrey Feike.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
Tevogen Bio, Inc.
![]() Tevogen Bio, Inc. BiotechnologyHealth Technology Tevogen Bio, Inc. is a late-stage biotech company based in Warren, NJ. Tevogen Bio is focused on developing accessible personalized immunotherapies using its pioneering technology, the exactcelltm platform, which produces scalable, rapidly available, unmodified allogeneic cytotoxic T lymphocytes (CTLs) for the treatment of cancers, viral infections, and the prevention of long-term complications of these conditions. Tevogen Bio's strategic partners share their values and mission, and their next-generation precision T cell platform is designed to provide increased specificity to eliminate malignant and virally infected cells while allowing healthy cells to remain intact. The company is committed to pioneering lifesaving innovations for viral diseases and cancers for which there is a high unmet need. The company was founded in 2020 by Ryan Saadi, who has been the CEO since then. | Director/Miembro de la Junta | 17/08/2022 | - |
Corporate Officer/Principal | 17/08/2022 | - |
Formación de Jeffrey Feike.
Tulane University (Louisiana) | Graduate Degree |
Estadísticas
Internacional
Estados Unidos | 3 |
Operativa
Director/Board Member | 2 |
Corporate Officer/Principal | 1 |
Graduate Degree | 1 |
Sectorial
Health Technology | 2 |
Consumer Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas privadas | 1 |
---|---|
Tevogen Bio, Inc.
![]() Tevogen Bio, Inc. BiotechnologyHealth Technology Tevogen Bio, Inc. is a late-stage biotech company based in Warren, NJ. Tevogen Bio is focused on developing accessible personalized immunotherapies using its pioneering technology, the exactcelltm platform, which produces scalable, rapidly available, unmodified allogeneic cytotoxic T lymphocytes (CTLs) for the treatment of cancers, viral infections, and the prevention of long-term complications of these conditions. Tevogen Bio's strategic partners share their values and mission, and their next-generation precision T cell platform is designed to provide increased specificity to eliminate malignant and virally infected cells while allowing healthy cells to remain intact. The company is committed to pioneering lifesaving innovations for viral diseases and cancers for which there is a high unmet need. The company was founded in 2020 by Ryan Saadi, who has been the CEO since then. | Health Technology |
- Bolsa de valores
- Insiders
- Jeffrey Feike
- Experiencia